Endocrine Pathology (2022) 33:1–2
https://doi.org/10.1007/s12022-022-09712-6

Special Issue On the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors: a New Primer for Endocrine Pathology Practice

Ozgur Mete[1,2]

Published online: 4 March 2022

Progress made in various aspects of endocrine pathology has provided much-needed information to establish the basis of a new classification of endocrine and neuroendocrine neoplasms. The 2022 WHO classification of endocrine and neuroendocrine tumors defines the new pathology standards that are essential in advancing the clinical and research practices in the field of endocrine and neuroendocrine neoplasia.

This special issue of *Endocrine Pathology* provides a comprehensive overview of the 2022 WHO classification of endocrine and neuroendocrine neoplasms. The invited authors include Dr. Ian A. Cree, the head of the WHO Classification of Tumors and Evidence Synthesis and Classification at the International Agency for Research on Cancer, and all endocrine disease-expert Editors as well as select authors who were extensively involved in the preparation of the new WHO classification of endocrine and neuroendocrine tumors.

Using a question-and-answer approach, the experts provide a practical overview on advances in tumor classification with novel diagnostic categories and terminologies, translational diagnostic and theranostic biomarkers, and molecular features of endocrine and neuroendocrine neoplasms that are useful to surgical pathologists, endocrinologists, oncologists, surgeons, researchers, patients, and any learner with an interest in endocrine and neuroendocrine neoplasms.

In this special issue, the pre-analytic and analytic technical aspects of tumor proliferation from counting mitoses (per mm^2) to the Ki67 proliferation index are discussed by Dr. Cree [1]. Manuscripts include the new classification of pituitary, thyroid, parathyroid, and adrenal cortical neoplasms, as well as paragangliomas and pheochromocytomas, and the entire spectrum of neuroendocrine neoplasms from head to toe [2–7]. In addition, a manuscript focusing on advances and updates in inherited endocrine and neuroendocrine neoplasia syndromes is included [8]. The final article of this special issue focuses on the future, highlighting questions and challenges for endocrine pathologists to address in the coming years [9].

I hope that this special issue of *Endocrine Pathology* will serve as a valuable reference for both the scientific and the medical audiences. I would like to thank all the authors for their contributions and all handling editors and reviewers for their efforts to ensure the highest standards for these review articles. I also acknowledge the invaluable support of our Executive Editor, Ms. Melissa Ramondetta, and the meticulous work provided by the editorial office as well as the outstanding work of our production coordinator, Ms. Razel Gerona-Avanzado, and her great team that enabled a smooth publication process during the COVID-19 pandemic.

Ozgur Mete, MD, FRCPC
Editor-in-Chief, *Endocrine Pathology.*

References

1. Cree IA. From Counting Mitoses to Ki67 Assessment: Technical Pitfalls in the New WHO Classification of Endocrine and Neuroendocrine Tumors. Endocr Pathol (2022). https://doi.org/10.1007/s12022-021-09701-1
2. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09703-7.
3. Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09707-3.

✉ Ozgur Mete
ozgur.mete2@uhn.ca

[1] Department of Pathology, University Health Network, Toronto, ON, Canada

[2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

4. Erickson LA, Mete O, Juhlin CC, Perren A, Gill AJ. Overview of the 2022 WHO Classification of Parathyroid Tumors. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09709-1.
5. Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09704-6.
6. Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra D, Papotti M, Asa SL. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09708-2.
7. Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, Papotti MG. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09710-8.
8. Nosé V, Gill A, Cameselle Teijeiro JM, Perren A, Erickson L. Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09705-5.
9. Asa SL, Erickson LA, Mete O. The next steps for Endocrine Pathology. Endocr Pathol (2022). https://doi.org/10.1007/s12022-022-09711-7.